This Month
CSL sees greying population as saviour in Ozempic battle
The biotech giant also outlined an inverse Uber-style surge fee to reward people donating blood outside peak hours.
- Updated
- Liam Walsh
September
Soul Patts ploughs nearly $1b into private markets
The increasing tilt toward the private markets in their annual results comes as investors see equities as too expensive.
- Primrose Riordan
Consulting firm McKinsey to pay $362m in latest US opioid settlements
Hundreds of US local governments and school districts alleged it fuelled an epidemic of addiction through its work for bankrupt OxyContin maker Purdue Pharma.
- Nate Raymond
- Analysis
- EU
The single company propping up an entire economy
Pharmaceutical giant Novo Nordisk’s first-mover advantage in weight-loss drugs has singled-handedly saved Denmark from recession. How long will the ride last?
- Hans van Leeuwen
Chemists protest medicine rule change in angry walk out
Hundreds of pharmacists disrupted parliament question time on Monday.
- Tom McIlroy
August
- Analysis
- Government Observed
How to double the university sector
A university degree will be almost mandatory to obtain future work, fundamentally challenging a system that was last reformed nearly 40 years ago.
- Tom Burton
- Opinion
- The AFR View
If chemists should prescribe, let supermarkets sell medicines
Having held firm on freeing up the dispensing rules in patients’ interest, Labor should now call out the policy hypocrisy of the pharmacy lobby.
- The AFR View
Coalition push to scrap 60-day prescriptions
The Coalition announced it would attempt to scrap the regulations letting people buy 60 days worth of medicines for the price of one script, up from 30 days.
- Ronald Mizen
July
Billionaire Bastas’ Arrotex posts near 50 per cent rise in profit
The country’s largest generic drug supplier, now fully owned by the businessman, produces treatments for hay fever, digestive health, as well as cold and flu.
- Primrose Riordan
- Analysis
- Illness
The alarming twist when using Ozempic for weight loss
Ozempic is a model appetite suppressant, improves blood glucose control, reduces insulin resistance and is effective for diabetes, but there are several unknowns.
- Jill Margo
Billionaire Bastas buys out pharma partners in $1b deal; UBS on hand
Street Talk can reveal KKR Credit and Goldman Sachs have co-invested with Bastas in the deal.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Done deal: George Clinical sold for $500m after FIRB snag
It is understood Hillhouse Capital settled on the acquisition this week and paid about $500 million for a controlling stake in George Clinical.
- Sarah Thompson, Kanika Sood and Emma Rapaport
New drug shown to slow Alzheimer’s progress
Dementia experts have hailed the results of a trial of the treatment, the second shown to alter the course of the crippling disease.
- Robert Langreth
Aussie cannabis player Little Green Pharma pins growth hopes on Europe
The medicinal cannabis sector has taken a buffeting, but Gina Rinehart-backed LGP hopes a new facility in Denmark will help it ride out the turbulence.
- Hans van Leeuwen
AstraZeneca drops on concern over lung cancer trial
The company also reported some deaths in the trial, raising safety concerns. The trial is continuing because the data isn’t fully mature yet.
- Thomas Mulier
June
Do drug companies have too much influence on medical students?
Universities have done little to protect medical students from the undue influence of pharmaceutical companies.
- Julie Hare
Pharmacy guild taps its favourite economist
It isn’t the first time the guild has turned to Henry Ergas for this kind of work.
- Myriam Robin
Exploiting the power of clean, green ‘Australian-made’ overseas
The label ‘Australian-made’ is a big drawcard for consumers in emerging markets, helping Vitex Pharmaceuticals to a 76 per cent growth rate on the Fast Global list.
- Prashant Mehra
Why this CEO thinks 454pc growth in his company is just the beginning
Telix Pharmaceuticals has topped the inaugural Financial Review Fast Global list, with offshore revenue driven by the US FDA’s approval for its prostate cancer screening tool.
- Michael Bailey
The acid test: why LSD is making a comeback
A new breed of biotech companies are reshaping traditional approaches to the treatment of mental health conditions such as depression.
- Julie Hare
